A convenient access to α V β 3 /α V β 5 integrin ligand conjugates: regioselective solid-phase functionalisation of an RGD based peptide

The cyclopeptide (-RGDfK-) is a potent and selective αVβ3/αVβ5 integrin ligand. A methodology for the conjugation of cyclo(-RGDfK-) through the regioselective derivatisation of lysine side chains, either in solution or directly on the solid support, is described. This provides a rapid and flexible chemical entry to conjugated integrin ligands bearing reporter groups for biological investigations or reactive chemical functions for the preparation of new vector systems.

[1]  Horst Kessler,et al.  Stereoisomeric Peptide Libraries and Peptidomimetics for Designing Selective Inhibitors of the αvβ3 Integrin for a New Cancer Therapy , 1997 .

[2]  Richard O. Hynes,et al.  Integrins: Versatility, modulation, and signaling in cell adhesion , 1992, Cell.

[3]  B. Nies,et al.  Surface Coating with Cyclic RGD Peptides Stimulates Osteoblast Adhesion and Proliferation as well as Bone Formation , 2000, Chembiochem : a European journal of chemical biology.

[4]  E. Giralt,et al.  Use of Alloc-amino acids in solid-phase peptide synthesis. Tandem deprotection-coupling reactions using neutral conditions , 1997 .

[5]  X. Dai,et al.  An improved synthesis of a selective αvβ3-integrin antagonist cyclo(-RGDfK-) , 2000 .

[6]  D. Cheresh,et al.  Requirement of vascular integrin alpha v beta 3 for angiogenesis. , 1994, Science.

[7]  Horst Kessler,et al.  N-methylated cyclic RGD peptides as highly active and selective αvβ3 integrin antagonists , 1999 .

[8]  K. Geoghegan,et al.  Site-directed conjugation of nonpeptide groups to peptides and proteins via periodate oxidation of a 2-amino alcohol. Application to modification at N-terminal serine. , 1992, Bioconjugate chemistry.

[9]  A. Giannis,et al.  Integrin Antagonists and Other Low Molecular Weight Compounds as Inhibitors of Angiogenesis: New Drugs in Cancer Therapy , 1997 .

[10]  D. Cheresh,et al.  Synergy between an antiangiogenic integrin alphav antagonist and an antibody-cytokine fusion protein eradicates spontaneous tumor metastases. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[11]  Horst Kessler,et al.  Radiolabeled αvβ3 Integrin Antagonists: A New Class of Tracers for Tumor Targeting , 1999 .

[12]  B. Nies,et al.  Selective RGD-Mediated Adhesion of Osteoblasts at Surfaces of Implants. , 1999, Angewandte Chemie.

[13]  A. Miller,et al.  Cell delivery, intracellular trafficking and expression of an integrin-mediated gene transfer vector in tracheal epithelial cells , 2000, Gene Therapy.